Hi guys, I know I am very late for the blog posting. But please provide feedback to my company.
It reminds me of the previous term where I enrolled late and had to send Martin email for my company and perform all the interesting assignment with my company which was the very fun to look at my company. Same is here in this semester course also. I was hoping to get the same kind of company as in the first term and crossed my finger and checked the excel file and found my company which was a health care company of Australia and named as Analytica. Their respective annual reports of three years can be found here: 2016, 2015, and 2014.
About my company
Analytica Limited is a Brisbane-based public company which is also recorded on the Australian Stock Exchange (ASX). It is a health care company of the Australia and the lead product of the Analytica is PeriCoach which is an e-health treatment system for women who are suffering from Stress Urinary Incontinence. The company is dedicated to the design, development and supply of class I and II medical devices. It is committed to make the medical devices of class I and class II and develop and design then supply to the people. The popular device of Analytica is composed of a device, web portal and smartphone app which works with pelvic floor muscles which is then communicated to a smartphone app and can be loaded to PeriCloud where physicians can monitor patient progress via with web portal.
The company has been granted the patent protection on 11th May, 2017 in Brisbane, Australia for the PeriCoach System. In addition PeriCoach is also granted to the patent protection in China, Japan, and USA. The article for patent protection is PeriCoach. The product has reached in the top priority in the global product which has thus maintained its investment in intellectual protection in major markets across the world. It also designed scientifically performing the exercise program to drive motivation and compliance on 4th May, 2017. The detail about the program can be found via Report. Chelsea Cornelius, Product Development Manager of Analytica was awarded the Medical Technology Association of Australia (MTAA) Outstanding Achievement Awards on 24th October, 2016. (Award Achievement)
I was satisfied with the company allocated by Martin because the company has the limited required information in the specific area which could be discussed in my report of company. The consolidated loss amounted to $ (3,881,472) after the income tax and represented a decrease on the loss of $1,434,132 result for the year ended on 30th June, 2015 of $ (5,315,604). There is increase for the market development of $173,928 to 1,938,283, research and development decreased by $893,617 to $2,469,665, administration costs increased by $172,856 to $1, 87,810. The net assets of the group have increased by $917,842 from 30th June, 2015 to $1,298,891 at 30th June, 2016. The capital of Analytica has been increased to 10% of the capital because of the support of INOY8 cornerstone investor and has announced the expenditure reduction program which extends the companies cash resources.